In early studies, it was found that its concentration also significantly decreases in various cardiovascular diseases, metabolic syndromes (low adiponectin levels are associated with obesity and insulin resistance), and type 2 diabetes [20,21,22,23,24,25,26,27,28]. Here, ADIPOQ is linked to cardiovascular disorder.